At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BNR Burning Rock Biotech Limited
Pre-Mkt 08-27 04:14:20 EDT
10.44
+0.64
+6.53%
High10.49Low9.26Vol3.57K
Open9.26D1 Closing9.80Amplitude12.55%
Mkt Cap110.10MTradable Cap34.76MTotal Shares10.55M
T/O35.07KT/O Rate0.11%Tradable Shares3.33M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Burning Rock CanCatch Custom MRD Kit Enters NMPA Innovative Device Special Review Procedure
Reuters  ·  08-25 23:06
Burning Rock CanCatch Custom MRD Kit Enters NMPA Innovative Device Special Review Procedure
Possible Turnaround For Burning Rock Biotech Insiders, Still Down CN¥1.4m
Simply Wall St.  ·  08-22
Possible Turnaround For Burning Rock Biotech Insiders, Still Down CN¥1.4m
Russian group claims to have hacked Shell and Philips, BNR reports
TIPRANKS  ·  08-17
Russian group claims to have hacked Shell and Philips, BNR reports
US Closing Bell | Megacaps resist mild pullback as Dow edges 0.1% lower
US Closing Bell  ·  08-11
US Closing Bell | Megacaps resist mild pullback as Dow edges 0.1% lower
Bulletin Resources addresses ASX concerns over late director trading disclosure
TIPRANKS  ·  07-09
Bulletin Resources addresses ASX concerns over late director trading disclosure
Bulletin Resources Director Increases Indirect Shareholding via On-Market Trade
TIPRANKS  ·  07-06
Bulletin Resources Director Increases Indirect Shareholding via On-Market Trade
Major Insider Move Signals Growing Confidence in Burning Rock Biotech
TIPRANKS  ·  07-03
Major Insider Move Signals Growing Confidence in Burning Rock Biotech
Burning Rock Biotech Director Han Yusheng Reports $6.42 Million ADS Purchase
Reuters  ·  07-02
Burning Rock Biotech Director Han Yusheng Reports $6.42 Million ADS Purchase
Burning Rock Biotech CEO Yusheng Han purchases 73,141 ADSs for $618,217
TIPRANKS  ·  07-02
Burning Rock Biotech CEO Yusheng Han purchases 73,141 ADSs for $618,217
Burning Rock Announces Founder’s Purchase of Its ADSs
GlobeNewswire  ·  07-02
Burning Rock Announces Founder’s Purchase of Its ADSs
China's Burning Rock Biotech Q1 revenue falls on lower test volumes
Reuters  ·  06-09
China's Burning Rock Biotech Q1 revenue falls on lower test volumes
Burning Rock Reports First Quarter 2026 Financial Results
THOMSON REUTERS  ·  06-09
Burning Rock Reports First Quarter 2026 Financial Results
Burning Rock Biotech Limited Q1 Adjusted Gross Margin 74.6%
THOMSON REUTERS  ·  06-09
Burning Rock Biotech Limited Q1 Adjusted Gross Margin 74.6%
Burning Rock Biotech Limited Q1 Revenue RMB 107.9 Million
THOMSON REUTERS  ·  06-09
Burning Rock Biotech Limited Q1 Revenue RMB 107.9 Million
Burning Rock Biotech Limited Q1 Net Income RMB -17.5 Million
THOMSON REUTERS  ·  06-09
Burning Rock Biotech Limited Q1 Net Income RMB -17.5 Million
Burning Rock Q1 FY26 net loss widens to RMB 17.5 million; revenue falls 18.9% to RMB 107.9 million
Reuters  ·  06-09
Burning Rock Q1 FY26 net loss widens to RMB 17.5 million; revenue falls 18.9% to RMB 107.9 million
Key NGS Certification Registration Halted; Burning Rock Biotech's Stock Plummets Over 40% in Five Days Amid Lack of Positive Catalysts
Stock News  ·  05-30
Key NGS Certification Registration Halted; Burning Rock Biotech's Stock Plummets Over 40% in Five Days Amid Lack of Positive Catalysts
Jefferies upgrades Burning Rock Biotech (BNR) to a Hold
TIPRANKS  ·  05-24
Jefferies upgrades Burning Rock Biotech (BNR) to a Hold
Bulletin Resources Corrects Chifley Drilling Update and Plans Deeper Gold Tests
TIPRANKS  ·  05-04
Bulletin Resources Corrects Chifley Drilling Update and Plans Deeper Gold Tests
Bulletin Resources Advances Lake Rebecca Drilling With Strong Cash Backing
TIPRANKS  ·  04-30
Bulletin Resources Advances Lake Rebecca Drilling With Strong Cash Backing
No data available

Introduction

Company Name.
Burning Rock Biotech Limited
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
The company is primarily engaged in precision oncology and early cancer detection. According to China Insights Consultancy, it was the No. 1 NGS-based cancer therapy selection company in China by number of patients tested in 2019, holding a 26.7% market share. Its cancer therapy selection platform is built on advanced technology, a comprehensive product portfolio, and a dual-pronged market-driven commercial infrastructure that serves large hospitals through an in-hospital model and smaller hospitals through a central laboratory model.
Issue price:
--